Orgenesis Inc
NASDAQ:ORGS

Watchlist Manager
Orgenesis Inc Logo
Orgenesis Inc
NASDAQ:ORGS
Watchlist
Price: 0.16 USD Market Closed
Market Cap: $1m

Net Margin

-3 827.8%
Current
Declining
by 1 244.6%
vs 3-y average of -2 583.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-3 827.8%
=
Net Income
$-34.4m
/
Revenue
$899k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-3 827.8%
=
Net Income
$-34.4m
/
Revenue
$899k

Peer Comparison

Country Company Market Cap Net
Margin
US
Orgenesis Inc
NASDAQ:ORGS
1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-3 827.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Orgenesis Inc
Glance View

Market Cap
1m USD
Industry
Biotechnology

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 151 full-time employees. The company went IPO on 2010-07-01. The firm is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The company has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.

ORGS Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-3 827.8%
=
Net Income
$-34.4m
/
Revenue
$899k
What is Orgenesis Inc's current Net Margin?

The current Net Margin for Orgenesis Inc is -3 827.8%, which is below its 3-year median of -2 583.2%.

How has Net Margin changed over time?

Over the last 3 years, Orgenesis Inc’s Net Margin has decreased from -209.1% to -3 827.8%. During this period, it reached a low of -10 445.5% on Dec 31, 2023 and a high of -38.7% on Jun 30, 2023.

Back to Top